Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig

Bongi Kim¹²³, Jun-Seop Shin¹²³ and Chung-Gyu Park¹²³*

¹Department of Microbiology and Immunology, ²Cancer Research Institute, ³Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea

CTLA-4Ig is regarded as an inhibitory agent of the T cell proliferation via blocking the costimulatory signal which is essential for full T cell activation. To improve applicability, we developed the CTLA-4Ig-CTKC in which the c-terminal lysine had been replaced by cysteine through single amino acid change. The single amino acid mutation of c-terminus of CTLA-4Ig was performed by PCR and was checked by in vitro transcription and translation. DNA construct of mutant form was transfected to Chinese hamster ovary (CHO) cells by electroporation. The purified proteins were confirmed by Western blot and B7-1 binding assay for their binding ability. The suppressive capacity of CTLA-4Ig-CTKC was evaluated by the mixed lymphocyte reaction (MLR) and in the allogeneic pancreatic islet transplantation model. CTLA-4Ig-CTKC maintained binding ability to B7-1 molecule and effectively inhibits T cell proliferation in MLR. In the murine allogeneic pancreatic islet transplantation, short-term treatment of CTLA-4Ig-CTKC prolonged the graft survival over 100 days. CTLA-4Ig-CTKC effectively inhibits immune response both in MLR and in allogeneic islet transplantation model, indicating that single amino acid mutation does not affect the inhibitory function of CTLA-4Ig. CTLA-4Ig-CTKC can be used in vehicle-mediated drug delivery system such as liposome conjugation.

INTRODUCTION

T cell costimulation is the most important concept in basic T cell immunology. Two types of signals provided by an antigen-presenting cell (APC) are essential for activation of T cells. Signal one is antigen-specific signal that is generated upon the engagement of T cell receptor (TCR) with the antigen (Ag) loaded in the major histocompatibility complex (MHC) on APCs. Signal two is produced by the binding between costimulatory receptors on T cells and their ligands expressed on APCs (1,2). Costimulation without TCR stimulation has no effect on T cells, but TCR stimulation with the absence of costimulation signal leads to T cell anergy (3).

One of the most important costimulatory signal enabling full activation of T cells is generated by binding between CD28 constitutively expressed on T cells and B7-1 or B7-2 on APC (4,5). In contrast, the interaction of B7 molecules with CTLA-4, a CD28 homologue provides inhibitory signals leading to down-regulation of the T cell response (6). CTLA-4 exhibits 10 to 100 times higher affinity for the B7 molecules compared to CD28.

Received on January 21, 2013. Revised on February 5, 2013. Accepted on February 12, 2013.

Keywords: Mutation, CTLA-4Ig, Costimulation, T cell
than CD28 (7). To use as T-cell inhibitory agent, the extracellular domain of CTLA-4 was fused with Fc portion of IgG to generate the soluble form of CTLA-4 called CTLA-4Ig. In the transplantation field, CTLA-4Ig can prevent graft rejection including pancreatic islet, liver and cardiac transplantation (8-10). In addition, many approaches have been tried to improve functional efficacy of CTLA-4Ig through changing amino acid near binding site to B7 such as belatacept (11) or conjugating a carrier material to CTLA-4Ig such as liposomes (12).

In the case of conjugating a carrier molecule, antibody or enzymes were generally modified with chemical agents such as SATA (succinimidyl-s-acetylthioacetate) to crosslink with another maleimide-activated carrier molecule. In this study, we developed a modified form of CTLA-4Ig, termed as CTLA-4Ig-CTKC to facilitate direct conjugation without any chemical agents to maleimide-activated carrier molecule. In this report, we demonstrated that CTLA-4Ig-CTKC has same functional efficacy as CTLA-4Ig without any functional loss associated with single amino acid mutation.

MATERIALS AND METHODS

Animals

BALB/c and C57BL/6 mice were purchased from the Koatech (Kyunggi-do, Korea) and were kept at the specific pathogen-free animal facilities of the Seoul National University College of Medicine.

Cell cultures

A hybridoma cell line, 4F10 secreting anti-mouse CTLA4 antibodies (HB304, American Type Culture Collection, Manassas, VA, USA) and P815B7.1 cells, B7-1 transfected mouse mastcytoma cell line (TIB-64, American Type Culture Collection, Manassas, VA, USA) were cultured and maintained with high glucose Dulbecco’s Modified Eagles Medium (DMEM, Gibco/BRL, Grand Island, NY, USA) containing 10% of heat-inactivated fetal bovine serum (FBS, Gibco/BRL, Grand Island, NY, USA) supplemented with 10 mM HEPES (Sigma-Aldrich Inc., St. Louis, MO, USA), 100 mM non-essential amino acids, 55 μM β-mercaptoethanol (β-ME) and 50 μg/ml gentamycin (Gibco/BRL, Grand Island, NY, USA).

CHO K-1 cells were also grown in DMEM for routine maintenance and in complete serum-free medium, Opti-CHO (Gibco/BRL, Grand Island, NY, USA) at mass culture for protein preparation, All of the cells were grown at 37°C in humidified atmosphere with 7% CO2.

DNA construct and transfection

The DNA construct of mouse CTLA-4IgG3 was provided by Dr. Jeffery A. Bluestone. All plasmid DNA were prepared by using the DNA preparation kit (Genemend, Seoul, Korea). Point mutation of IgG3 c-terminus was proceeded by PCR method to make c-terminus residue from AAA (lysine) to ACA (cysteine), PCR reaction was performed using Han-pfu polymerase (Genemend, Seoul, Korea) with following two primers: sense, 5'-GTG GTA CTT ATG AAA-3'(18 mer); antisense, 5'-GCT CTA GAG CTG TTC TCA ACA ACC AGG GGA-3'(34 mer) which contains codon for cysteine (bold character). This reaction was set up as follows: 1 ng of CTLA-4Ig DNA, 0.2 μM of sense and anti-sense primer, 5 μl of 10× reaction buffer (supplied with Han-pfu polymerase), 10 mM dNTP, 1 μl Han-pfu polymerase, in a final volume of 50 μl. Reaction cycle was as follows: 94°C 3 min for pre-denaturation, 35 cycles of 94°C for 1 min, 58°C for 1 min, 72°C for 1 min and 72°C 10 min for post elongation. The PCR product was digested by Kpn I and XbaI and ligated to pcDNA3.1 (Invitrogen Life Technology, Carlsbad, CA, USA). DNA construct was then transformed into E. coli DH5 alpha followed by preparing plasmid DNA. Mutation site was confirmed by DNA sequencing analysis, CHO cells were collected at log-phase growth, and electroporation was performed as follows. Each 10 μg of both pcDNA3.1-CTLA4 wild type and pcDNA3.1-CTLA4IgG3-CTKC was mixed with each 5×106 cells in a 0.4-cm electroporation cuvette and electroporated at 25 μF and infinite resistance using 300 volt in Gene pulser X cell system (Bio-RAD Laboratories, Hercules, California, USA) and plated into 100 mm culture dish.

In vitro transcription and translation

The TNT® Quick Coupled Transcription/Translation System (Promega, Madison, MI, USA) was used for in vitro transcription/translation and TranscendTM Non Radioactive Translation Detection System (Promega, Madison, MI, USA) was used for detecting the translation products. One μg of both pcDNA3.1-CTLA4Ig and pcDNA3.1-CTLA4IgG3 was transcribed and translated in a 50 μl reaction mixture containing 40 μl of TNT®, 17 quick master mix, 1 mM methionine, and 2 μl of TranscendTM Biotin-Lysyl-RNA at 30°C for 90 minutes. The products of reaction were separated by SDS-PAGE and transferred to a PVDF membrane. The transfer was performed in the transfer buffer containing 193 mM glycine, 25
mM Tris and 20% methanol for 2 hours at 100 V at 4°C. The membrane was then submerged in incubation buffer containing 5% non-fat dried milk and 0.1% Tween-20 in 20 mM Tris/HCl (pH 7.5)/137 mM NaCl (TBST) and left for 3 hours at room temperature. The detection antibody, streptavidin-HRP conjugate was diluted 1 : 10,000 in TBST and added to the membrane followed by incubation for 2 hours at room temperature. The development of positive signal was performed using Supersignal West Pico Chemiluminescent substrate (Pierce, Thermo scientific, Rockford, IL, USA).

Transfection, selection and mass culture
One day after incubation of electroporated CHO cells, cells were harvested and split into 20 plates of 100 mm dish with media containing 2 mg/ml of G418 (Geneticin, Gibco Laboratories, Grand Island, NY, USA) to select stable clones. For selecting stable clones, transfected cells were incubated for 2 ~ 3 weeks in the presence of G418 until cell colonies were visible. Ninety six cell colonies were picked on an inverted light microscope using micropipette and transferred to 96-well culture dish (Nunc, Rochester, NY, USA) with 0.2 ml of culture media containing 2 mg/ml of G418. Individual colony was cultured and a few clones were sorted out by high expression level of the secreted protein. The sorted cells were sub-cultured and adapted in complete serum free medium, Opti CHO (Gibco/BRL, Grand Island, NY, USA) with 0.2 ml of culture media containing 2 mg/ml of G418. Individual colony was cultured and a few clones were sorted out by high expression level of the secreted protein. The sorted cells were sub-cultured and adapted in complete serum free medium, Opti CHO (Gibco/BRL, Grand Island, NY, USA). The selected cells (3 × 10^7) were transferred to Triple flask (Nunc, Rochester, NY, USA) for mass culture with 250 ml of Opti CHO medium.

4F10 sepharose bead preparation
The hamster anti-mouse CTLA-4 mAb 4F10 was purified from hybridoma cell culture supernatants using standard protein A-sepharose chromatography. One gram of CNBr activated sepharose Fast flow (GE Healthcare, San Jose, CA, USA) was swollen with 1 mM HCl for 15 min at room temperature. The swollen gel was transferred to sintered glass funnel and washed with 200 ml of 1 mM HCl. After washing gel with 5 ml coupling buffer (0.1 M NaHCO3, 0.5 M NaCl), gel was transferred to tube containing 20 mg of anti-mouse CTLA-4 monoclonal antibody, 4F10, in coupling buffer and incubated for 2 hours at room temperature with constant rotation. After coupling reaction, gel was incubated with blocking buffer (0.2 M Glycine, pH 8.0) to block the excess active group for 2 hours at room temperature. This gel was then poured into sterile empty chromatography column followed by washing with the four times alternating between low pH wash buffer (0.1 M acetic acid, 0.5 M NaCl) and coupling buffer and stored at 4°C with PBS (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) containing a preservative (sodium azide 0.05%) until use.

Measurements of quantification of secreted protein
To quantify the amount of CTLA-4 Ig during selection and mass culture, sandwich-enzyme-linked immunosorbent assay (ELISA) was performed by following antibodies: Anti-CTLA4 monoclonal antibody (4F10) as capture antibody and HRP conjugated anti-mouse IgG antibody as detecting antibody.

Two μg/ml of anti-CTLA4 monoclonal antibody diluted in PBS was coated on 96-well MaxiSorpELISA plate (Nunc, Rochester, NY, USA) and incubated overnight at 4°C and washed 3 times with PBS containing 0.05% of Tween-20 (PBST) (Sigma-Aldrich Inc., St. Louis, MO, USA). After blocking of each well with 5% skim milk (Difco, Spark, MD, USA) and washed 3 times with PBST, the HRP conjugated anti mouse IgG (GeneTex, Irvine, CA, USA) diluted in 1 : 100,000 was added in each well for 2 hours at room temperature and washed 5 times with PBST. The HRP conjugated anti mouse IgG was incubated with 0.2 ml of TMB substrate solution (eBioscience, San Diego, CA, USA) with a preservative (sodium azide 0.05%) until use. The plate was read at an absorbance of 450 nm.

Preparation of CTLA-4 Ig
All of CTLA-4Igs in either wild or mutant form were produced in our laboratory. Before handing with mutant form of CTLA-4 Ig, we have done many in vitro and in vivo experiments with wild type CTLA-4 Ig. When purifying this wild type form, protein G affinity column was enough for obtaining pure CTLA-4 Ig. However, mutating c-terminal lysine to cysteine, a significant amount of mutant form of CTLA-4 Ig got through protein G column, indicating single amino acid mutation cause some structural change to yield lower binding affinity to protein G. Therefore, we prepared a 4F10 sepharose bead by ourselves and devised a new purification method. To rule out any structural and/or functional change associated with a new purification method, we have purified wild type and mutant form of CTLA-4 Ig described in this manuscript.

Total culture supernatant was harvested from several replica cultures and centrifuged at 12,000 g at 4°C by the Avanti
RESULTS

Generation of DNA construct of both CTLA-4 IgG3 and mutant

Mouse CTLA-4 Ig construct was kindly provided by Dr. Bluestone in UCSF, while mutant form of CTLA-IgG3 was made by point mutation with PCR method. Amino acid at the end of CH3 domain of IgG3 is lysine, but this residue was changed to cysteine by mutagenesis. According to construct diagram, nucleotide sequence at this site was changed from AAA (Lys) to TGT (Cys) (Fig. 1A). The size of PCR product containing mutation site was confirmed by 1% agarose gel electrophoresis as 1,2 Kb band in Fig. 1B. This construct was subcloned into the eukaryotic expression vector, pcDNA3.1, and full DNA sequence of PCR product was confirmed by DNA sequencing analysis. The protein expression of pcDNA3.1-CTLA-4 IgG3 was further confirmed by the TNT® Quick Coupled Transcription/Translation System (Promega, Madison, WI, USA), SDS-PAGE and Western blotting. The results showed that both wild type and mutant type proteins yielded about 45 KDa protein band (Fig. 1C).

Purification of CTLA-4 Ig and CTLA-4 Ig-CTKC

To make a stable cell lines, the purified DNA constructs were transfected into CHO cell lines with electroporation method. Several clones exhibiting high levels of secretion of each CTLA-4 Ig or CTLA-4 Ig-CTKC proteins were established. After establishment of stable cell lines, cells were adapted to serum-free CHO cell medium to start mass culture. Total 6 liters of culture supernatant were harvested in every purification cycle. The mutant form of CTLA-4 Ig was purified by using anti-CTLA4 mAb, 4F10, conjugated sepharose bead because of its low binding affinity to protein G sepharose beads (data not shown). Purified protein was identified as 55 KDa under reducing condition and 110 KDa under non-reducing condition in SDS-PAGE (Fig. 2). These results indicate that the secreted proteins from cells have a divalent CTLA4 molecule and slight increase in the size of protein might be due to glycosylation of target protein in CHO cells.
B7-1 binding assay of purified CTLA-4Ig-CTKC

To test whether purified CTLA-4Ig-CTKC binds to its target molecules, B7-1 (CD80), varying amounts of purified protein were added to B7-1 expressing P815 cell line, P815B7-1. As shown in Fig. 3, CTLA-4IgG3-CTKC completely bound to B7,1 at 50 ng/ml of concentration. The mean fluorescence intensity of both CTLA-4Ig and CTLA-4Ig-CTKC increased in a dose-dependent manner from 50 ng/ml to 1 μg/ml of proteins.
Especially, CTLA-4Ig-CTKC had a similar binding efficacy compared with CTLA-4Ig although binding affinity of CTLA-4Ig-CTKC was slightly lower than that of CTLA-4Ig (Fig. 3 and 4). These results showed that CTLA-4Ig-CTKC could bind its ligand similarly as CTLA-4Ig.

The inhibitory effects of CTLA-4Ig-CTKC on MLR response
To investigate a possible effect of CTLA-4Ig in blocking the B7 molecule on APC, both CTLA-4Ig and CTLA-4Ig-CTKC were added to MHC-disparate allogeneic (BALB/c and C57BL/6) MLR condition. ^H-thymidine uptake by proliferating T cells from C57BL/6 mice splenocytes was measured. Count per minute (CPM) values increased over 50,000 at 72 hours in time-dependent manner in untreated control group (0 μg/ml). However, when CTLA-4Ig or CTLA-4Ig-CTKC was treated (0.5~6.0 μg/ml), proliferative responses were dramatically decreased in a dose-dependent manner (Fig. 4). This result demonstrated that CTLA-4Ig-CTKC also had inhibitory function on T cell proliferation in vitro similarly as CTLA-4Ig.

The CTLA-4Ig-CTKC was able to prolong islet graft survival similarly as CTLA-4Ig
To further confirm about the functional efficacy of CTLA-4Ig-CTKC, both CTLA-4Ig and CTLA-4Ig-CTKC were used in the allogeneic pancreatic islet transplantation model. Diabetic C57BL/6 mice received the isolated islet from Balb/c mice. As shown in Fig. 5, the animal treated with CTLA-4Ig-CTKC maintained blood glucose level over 100 days similarly as CTLA-4Ig-treated group. This result showed that CTLA-4Ig-CTKC can effectively inhibit CD28-mediated costimulatory sig-
C-terminal K to C Mutant Form of CTLA-4Ig
Bongi Kim and Chung-Gyu Park

22
IMMUNE NETWORK Vol. 13, No. 1: 16-24, February, 2013

Figure 4. Inhibition of T cell proliferation of CTLA-4Ig-CTKC on the allogenic MLR. Splenocytes from C57BL/6 mice (5 x 10^5) were stimulated with equal number of irradiated splenocytes from BALB/c mice in the total volume of 0.2 ml and the different amounts of either CTLA-4Ig (A) or CTLA-4Ig-CTKC (B) were added at the same time. After 24, 48 and 72 hours incubation, 1 μCi of ^3H-thymidine was added to each sample for 18 hours. The amount of ^3H-thymidine uptake by proliferating T cells in each well was estimated by counting per minute in the micro-beta counter.

Figure 5. Survival plots of mouse pancreatic islet allografts. The donor mouse (Balb/C) pancreatic islet cells were purified after collagenase digestion as described in material and methods. Diabetic recipient B6 mice received 500 IEQ of islets under left side kidney capsule. (A) Immediately after islet transplantation, B6 mice were injected with 50 μg of CTLA-4Ig every other day for 14 days intraperitoneally (n=2). All of these mice kept their graft over 80 days. (B) Animals were treated with 50 μg of CTLA-4Ig-CTKC (n=3) according to same injection procedure.

DISCUSSION

In this study, CTLA-4Ig-CTKC was generated by point mutation at the end of Fc portion in IgG3 and its immunological function was examined in vitro and in vivo. Our results showed that single amino acid substitution in CTLA-4Ig-CTKC does not affect its function as revealed by similar affinity to B7-1 molecule, prevention of T cell activation in allogeneic MLR reaction and prolongation of allogeneic islet graft in transplantation model.

CTLA-4Ig has been developed as an effective CD28 antagonist. The mechanistic basis for CTLA-4Ig function in vivo has increasingly become clear. CTLA-4Ig has been shown to be effective in the treatment of autoimmune diseases and thus approved by the Food and Drug Adminstration (FDA) (Abatacept, Bristol-Myers Squibb, NY, USA) for the treatment of rheumatoid arthritis (14-16). More recently, an improved version of Abatacept termed as LEA29Y with respect to higher affinity and avidity than CTLA-4Ig (Belatacept, Bristol-Myers Squibb, NY, USA) was developed and its efficacy was tested in the phase III clinical trial study in kidney transplantation (17-21). Another approach to increase affinity and avidity of CTLA-4Ig reported so far was to conjugate CTLA-4Ig on the surface of stealth liposomes such as PEG-PE liposomes (12). In that study, CTLA-4Ig conjugated to liposomes had been shown to improve the avidity of CTLA-4Ig binding to B7 molecule by its multivalent effect, but most of the injected CTLA-4Ig liposome was trapped in liver and spleen via non-specific binding to Fc receptor (12). The usage of mouse

nal in allantigen specific T cells in vivo.
IgG3 for CTLA-4Ig might be a solution to overcome this problem because Fc portion of mouse IgG3 was known to have a low affinity for Fc receptors (22). In addition, another way to improve CTLA-4Ig’s efficacy would be to give unidirectional orientation on the liposomes. To this end, a mutant form of CTLA-4IgG3, termed as CTLA-4Ig-CTKC, was developed by changing the c-terminal end of IgG3 from lysine to cysteine. We suggest that this cysteine is directly reactive to maleimide-activated carrier materials without chemical modification of CTLA-4Ig such as succinimidyl-s-acetylthioacetate (SATA) for creating free thiol group (-SH).

In protein engineering, a single amino acid substitution may yield problems such as loss of binding affinity, irreversible aggregation, and instability. Therefore, mutant proteins should be tested whether they maintain binding affinity and function. CTLA-4Ig-CTKC actually had a lower binding affinity to protein G sepharose column compared with CTLA-4Ig, leading us to find another purification strategy. Fortunately, CTLA-4Ig-CTKC was successfully purified by using 4F10-sepharose beads made in house and its immunological function was examined in vitro and in vivo. CTLA-4Ig-CTKC was able to suppress proliferation of T cells in MLR similarly as CTLA-4Ig and also bound B7-1 molecule in the binding assay although binding affinity was slightly lower than that of wild type. This propensity was also observed in the allogeneic islet transplantation model. It is well known that CTLA-4Ig induces T cell-mediated tolerance and thus achieve long-term graft survival in the transplantation model. As shown in Fig. 5, CTLA-4Ig-CTKC-treated mice also maintained blood glucose level over 100 days. This result clearly demonstrated that the functional efficacy of CTLA-4Ig-CTKC was not altered and thus can be used for further application procedure.

In conclusion, a modified form of CTLA-4IgG3, CTLA-4Ig-CTKC, has a high affinity to B7-1 and also inhibits T cell proliferation. It is possible that CTLA-4Ig-CTKC can be directly conjugated to maleimide-activated carrier materials such as liposomes. Further study is needed to test whether conjugated CTLA-4Ig-CTKC liposomes would have more potent immune suppressive ability than CTLA-4Ig.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Project No. A040004).

CONFLICTS OF INTEREST

The authors have no financial conflict of interest.

REFERENCES

1. Lenschow, D. J., T. L., Walunas, and J. A. Bluestone, 1996, CD28/B7 system of T cell costimulation, Annu. Rev. Immunol. 14: 233-258.
2. Laferty, K. J., S. J. Prowse, C. J. Simonovic, and H. S. Warren, 1985, Immunobiology of tissue transplantation: a return to the passenger leukocyte concept, Annu. Rev. Immunol. 1: 143-175.
3. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson, 1994, The B7 and CD28 receptor families, Immunity, Today 15: 321-331.
4. Salomon, B. J. A. Bluestone, 2001, Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation, Annu. Rev. Immunol. 19: 225-252.
5. Greenfeld, E. A., K. A. Nguyen, and V. K. Kuchroo, 1998, CD28/B7 costimulation: a review, Crit. Rev. Immunol. 18: 399-418.
6. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity 1: 405-413.
7. Tef, W. A., M. G. Kirchhof, and J. Madrinas, 2006, A molecular perspective of CTLA-4 function, Annu. Rev. Immunol. 24: 65-97.
8. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone, 1992, Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig, Science 257: 789-792.
9. Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R. Q. Wei, M. I., Gibson, X. G. Zheng, S. Myrdal, and D. Gordon, et al, 1992, T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo, Proc. Natl. Acad. Sci. U. S. A. 89: 11102-11105.
10. Li, W., P. Liu, Z., Wang, L., Wang, J. J., Pung, A. W. Thomson, and S. Qian, 2001, Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors, Transplantation 72: 1423-1432.
11. Larsen, C. P., T. C. Pearson, A. B. Adams, P. Tso, N. Shirasugi, E. Strobert, D. Anderson, S. Cowan, K. Price, J. Naemura, J. Einsewiler, J. Greene, L. A. Turk, J. Bajorath, R. Townsend, D. Hagerty, P. S. Linsley, and R. J. Peach, 2005, Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4Ig with potent immunosuppressive properties, Am. J. Transplant. 5: 443-453.
12. Park, C. G., C. S. Thiex, K. M. Lee, G. L. Szot, J. A. Bluestone, and K. D. Lee, 2003, Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution, Pharma, Res. 20: 1299-1308.
13. Lacy, P. E. and M. Kostianovsky, 1967, Method for the iso-
lation of intact islets of Langerhans from the rat pancreas, 
*Diabetes* 16: 35-39.

14. Abrams, J. R., M. G. Lebwohl, C. A. Guzzo, B. V. Jegasoathy, M. T. Goldfarb, B. S. Goffe, A. Menter, N. J. Lowe, G. Krueger, M. J. Brown, R. S. Weiner, M. J. Birkhofer, G. I. Wamer, K. K. Berry, P. S. Linsley, J. G. Krueger, H. D. Ochs, S. I. Kelley, and S. Kang. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. *J. Clin. Invest.* 103: 1243-1252.

15. Genovese, M. C., J. C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah, T. Li, R. Aranda, D. T. Hagerty, and M. Dougados. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, *N. Engl. J. Med.* 353: 1114-1123.

16. Kremer, J. M., R. Westhoven, M. Leon, E. Di Giorgio, R. Allen, S. Steinfield, A. Russell, M. Dougados, P. Emery, I. F. Nuamah, G. R. Williams, J. C. Becker, D. T. Hagerty, and I. W. Moreland. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N. Engl. J. Med.* 349: 1907-1915.

17. Kaplan, B. 2010. Belatacept: the promises and challenges of belatacept and costimulatory blockade, *Am. J. Transplant.* 10: 441-442.

18. Larsen, C. P., J. Grinyó, J. Medina-Pestana, Y. Vannreten-ghem, F. Vincenti, B. Bresnan, J. M. Campistol, S. Florman, C. Rial Mdel, N. Kumar, A. Block, G. Di Russo, G. S. Lin, P. Garg, and B. Charpentier. 2010. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies, *Transplantation* 90: 1528-1535.

19. Vincenti, F., G. Blancho, A. Durrbach, P. Friend, J. Grinyó, P. F. Hollaran, J. Klempnauer, P. Lang, C. P. Larsen, F. Mühlbacher, B. Nashan, J. P. Souillou, Y. Vannrengenhem, T. Wekerle, M. Agarwal, S. Gujrathi, J. Shen, R. Shi, R. Townsend, and B. Charpentier. 2010. Five-year safety and efficacy of belatacept in renal transplantation, *J. Am. Soc. Nephrol.* 21: 1987-1996.

20. Vincenti, F., B. Charpentier, Y. Vannrengenhem, L. Rostaing, B. Bresnahan, P. Darji, P. Massari, G. A. Mondragon-Ramirez, M. Agarwal, G. Di Russo, C. S. Lin, P. Garg, and C. P. Larsen. 2010. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study), *Am. J. Transplant.* 10: 535-546.

21. Durrbach, A., J. M. Pestana, T. Pearson, F. Vincenti, V. D. Garcia, J. Campistol, C. Rial Mdel, S. Florman, A. Block, G. Di Russo, J. Xing, P. Garg, and J. Grinyó. 2010. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study), *Am. J. Transplant.* 10: 547-557.

22. Alegre, M. L., J. Y. Tso, H. A. Sattar, J. Smith, F. Desalle, M. Cole, and J. A. Bluestone. 1995. An anti-murine CD28 monovalent antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity, *J. Immunol.* 155: 1544-1555.